PTIX (Protagenic Therapeutics) Tariff Resilience Score: 5/10 (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PTIX Protagenic Therapeutics Inc PTIX
22 GF Score
Price $0.18
! 2 Warning Signs
View Full Analysis

What is Protagenic Therapeutics Tariff Resilience Score?

Protagenic Therapeutics PTIX +8.02% 22 Tariff Resilience Score is 5 as of Aug. 01, 2026. GuruFocus rates PTIX with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,368 Biotechnology companies, Protagenic Therapeutics ranks better than 62.43% on this metric.

Protagenic Therapeutics has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Protagenic Therapeutics has PTIX faces moderate tariff vulnerability due to its reliance on international suppliers for R&D materials. The biotech industry has some tariff exemptions, but changes can affect costs. The company has limited pricing power but can explore alternative suppliers.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Protagenic Therapeutics might have Average Resilient.

Protagenic Therapeutics  (OTCPK:PTIX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Protagenic Therapeutics Tariff Resilience Score Related Terms

PTIX vs CERO, CYTOF, CARM: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Protagenic Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Protagenic Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protagenic Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Protagenic Therapeutics's Tariff Resilience Score falls into.


PTIX
22GF Score
Protagenic Therapeutics Inc PTIX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Protagenic Therapeutics (PTIX) has a Tariff Resilience Score of 5 as of Aug. 01, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Protagenic Therapeutics ranks #514 out of 1368 companies in the Biotechnology industry, placing it in the top 37.6%.
Is Protagenic Therapeutics' Tariff Resilience Score too high?
Protagenic Therapeutics' current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Protagenic Therapeutics' value of 5 is 25% above this industry median. Based on the distribution chart, Protagenic Therapeutics ranks #514 out of 1368 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Protagenic Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Protagenic Therapeutics' Tariff Resilience Score compare to CERO and CYTOF?
According to the Biotechnology industry distribution chart, Protagenic Therapeutics ranks #514 out of 1368 companies for Tariff Resilience Score. This puts Protagenic Therapeutics in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Protagenic Therapeutics' value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,368 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Protagenic Therapeutics's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Protagenic Therapeutics's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagenic Therapeutics stock overvalued right now?
Protagenic Therapeutics (PTIX) has a current Tariff Resilience Score of 5. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Protagenic Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Protagenic Therapeutics (PTIX), the current Tariff Resilience Score is 5 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Protagenic Therapeutics Business Description

Address 149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
22GF Score

Get the complete analysis for PTIX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.18
Price